Acute Disseminated Encephalomyelitis

Acute disseminated encephalomyelitis (ADEM) is an acute, typically monophasic inflammatory demyelinating disease of the central nervous system (CNS), characterized by widespread perivenular inflammation and myelin loss that most commonly develops in children within days to weeks following a viral infection or, less frequently, a vaccination. Clinically, it presents with an abrupt onset of encephalopathy accompanied by multifocal neurological deficits, and its pathological signature—scattered, patchy demyelination centered on small veins throughout the brain and spinal cord—distinguishes it from the confluent, more chronic demyelinating lesions of multiple sclerosis.

Background

ADEM belongs to the family of acquired demyelinating diseases of the CNS, a group that also includes multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD). The condition is generally regarded as immune-mediated: an external trigger, usually an infection, is thought to provoke an aberrant autoimmune response directed against components of myelin, such as myelin basic protein or myelin oligodendrocyte glycoprotein. Because the neurological symptoms typically follow the inciting event by a latent interval of roughly two days to four weeks, ADEM is classified as a "post-infectious" or "post-vaccinal" disorder rather than a direct infection of the nervous system.

The disease bears a close relationship to experimental autoimmune encephalomyelitis (EAE), the principal animal model of autoimmune CNS inflammation. EAE can be induced in laboratory animals by immunization with myelin antigens, and its neuropathological features closely mirror those of human ADEM. This correspondence has made ADEM a central reference point for studying mechanisms of CNS autoimmunity, including molecular mimicry, breach of the blood–brain barrier, and autoreactive T-cell activation.

Historical Background

Neurological complications following exanthematous infections were recognized as early as 1790, when Lucas described encephalomyelitic syndromes occurring after measles. Throughout the nineteenth century, clinicians documented similar illnesses after vaccination, particularly smallpox vaccination, giving rise to the older term "post-vaccinal encephalomyelitis." Westphal's account in 1860 is often cited among the earliest systematic descriptions of post-vaccinal neurological disease.

The disorder attracted renewed attention in the early twentieth century with the widespread use of neural-tissue rabies vaccines, which caused post-vaccinal encephalomyelitis in a small but significant proportion of recipients. The pivotal conceptual advance came in the 1930s, when Rivers and Schwentker demonstrated that repeated injection of brain tissue into laboratory animals produced a demyelinating encephalomyelitis, establishing an immunological basis for the human disease. Later refinements of this model using myelin antigens and complete Freund's adjuvant produced the modern EAE paradigm.

With the global eradication of smallpox and the replacement of neural-tissue rabies vaccines by safer cultured-cell products, vaccine-associated ADEM has become rare. In contemporary practice, the overwhelming majority of cases follow common infections, and the modern term "acute disseminated encephalomyelitis" reflects the recognized immunological continuity between post-infectious and post-vaccinal forms.

Epidemiology

ADEM is predominantly a disease of childhood, although cases occur at any age. Estimated incidence in children ranges from approximately 0.2 to 0.8 per 100,000 person-years, with the highest rates in children under ten years of age; the median age at onset is commonly reported between five and eight years. Adult ADEM is considerably rarer, with incidence estimates an order of magnitude lower. Many series report a slight male predominance, and a seasonal clustering in winter and spring has been observed in several populations, consistent with an infectious trigger.

Before routine measles immunization, post-measles ADEM complicated roughly one in 1,000 measles cases; contemporary post-vaccinal incidence following modern vaccines is far lower. Reported mortality in recent cohorts is approximately one to five percent, a substantial improvement over historical figures.

Pathogenesis

The prevailing hypothesis holds that ADEM results from a transient, self-limited autoimmune attack on CNS myelin triggered by a systemic infection or vaccination. Several mechanisms have been proposed, and they are not mutually exclusive:

• Molecular mimicry. Peptide sequences shared between an infectious agent and myelin proteins may activate T lymphocytes or antibodies that subsequently cross-react with host myelin antigens.
• Epitope spreading. Tissue injury during the primary illness may release sequestered myelin antigens, provoking secondary immune responses against additional epitopes.
• Blood–brain barrier disruption. The inciting systemic inflammatory response may transiently impair the blood–brain barrier, permitting entry of activated immune cells and humoral factors into the CNS.
• Humoral autoimmunity. Detection of serum IgG antibodies against myelin oligodendrocyte glycoprotein (MOG-IgG) in a substantial proportion of patients—up to half or more of affected children—has established MOG as a frequent target antigen, although antibody-negative cases are common and other antigens may be involved.

Neuropathologically, classic ADEM shows perivenular sleeves of lymphocytes and macrophages with segmental demyelination surrounding small venules, diffusely distributed throughout the cerebral hemispheres, brainstem, cerebellum, and spinal cord. Axons are relatively preserved, and the perivenular pattern of myelin loss contrasts sharply with the large, confluent plaques and more prominent periplaque inflammation characteristic of chronic MS.

Clinical Presentation

ADEM characteristically begins abruptly, often preceded by a prodromal febrile illness one to four weeks earlier. The clinical hallmark is acute encephalopathy—altered consciousness or behavior ranging from irritability and confusion to somnolence, stupor, or coma—which is required for the diagnosis and distinguishes ADEM from most presentations of MS. Fever, headache, vomiting, and meningism may accompany the onset.

Focal neurological deficits are multifocal and depend on lesion distribution. Common manifestations include:

• Hemiparesis or quadriparesis, reflecting cerebral or spinal cord involvement;
• Acute ataxia, frequently caused by cerebellar lesions;
• Cranial nerve palsies, most often involving ocular motility and facial muscles;
• Visual loss from optic neuritis, which is frequently bilateral in ADEM;
• Transverse myelitis with sensory loss, sphincter dysfunction, and paraparesis;
• Seizures, occurring in a minority of patients, occasionally in the form of status epilepticus;
• Speech disturbance, including aphasia and dysarthria.

The syndrome evolves over hours to days and typically reaches its maximum within days, distinguishing its tempo from the more subacute progression of many infections and neoplastic processes.

Diagnostic Evaluation

Magnetic resonance imaging is indispensable to diagnosis. Typical findings include large (often >1–2 cm), poorly marginated, asymmetric lesions in the subcortical and periventricular white matter, with frequent involvement of the cerebellum, brainstem, and spinal cord. Involvement of deep gray matter structures—thalami and basal ganglia—in a substantial proportion of patients is a characteristic clue that favors ADEM over MS. Lesions may enhance with gadolinium, but uniform concurrent enhancement of all lesions is unusual; their enhancement tends to be heterogeneous. On follow-up imaging, lesions often regress or resolve completely.

Cerebrospinal fluid (CSF) examination commonly shows mild to moderate lymphocytic or mononuclear pleocytosis and an elevated protein concentration, whereas oligoclonal bands—nearly ubiquitous in adult MS—are typically absent in ADEM, a finding of substantial differential value in children.

Serological testing for MOG-IgG is now standard in many centers, given its frequency in ADEM and its implications for prognosis and long-term monitoring. Electroencephalography typically reveals diffuse background slowing commensurate with encephalopathy. Additional laboratory studies are directed at excluding alternative causes, including infectious encephalitis, metabolic disorders, vasculitis, and malignancy.

Diagnostic Criteria

In 2007, the International Pediatric Multiple Sclerosis Study Group (IPMSSG) proposed consensus criteria for ADEM, revised in 2012. The essential requirements are:

1. A first multifocal clinical CNS event, presumed inflammatory in cause;
2. Encephalopathy that cannot be explained by fever;
3. No new symptoms or MRI findings emerging more than three months after onset;
4. Brain MRI showing diffuse, poorly demarcated, large (>1–2 cm) lesions predominantly in the cerebral white matter, with relative sparing of periventricular white matter;
5. Normal or nonspecific preceding neuroimaging, when available.

Under the 2012 framework, a second encephalopathic event occurring three or more months after, or more than four weeks after completion of steroid therapy for, the initial episode is classified as multiphasic ADEM (MDEM); non-encephalopathic relapses prompt reconsideration of the diagnosis, generally toward MS or MOGAD. Criteria published in 2022 by an international panel further distinguished ADEM from MOGAD, classifying MOG-IgG–positive presentations under the unified diagnosis of MOG antibody–associated disease while acknowledging ADEM-with-MOG-antibodies as a recognized phenotype.

Differential Diagnosis

The differential diagnosis is broad and includes: multiple sclerosis, particularly in adolescents and adults; neuromyelitis optica spectrum disorder; infectious encephalitis, including herpes simplex virus and other viral etiologies; CNS vasculitis; neurosarcoidosis and other inflammatory disorders; primary and metastatic CNS tumors or lymphoma; mitochondrial encephalopathies, such as Leigh syndrome and MELAS; and autoimmune encephalitides associated with neuronal antibodies. In adults, a diagnosis of ADEM warrants particularly rigorous scrutiny, because classical ADEM-like presentations are more frequently reclassified as MS, MOGAD, or other entities upon follow-up.

Treatment and Management

Evidence from randomized trials is limited, and treatment rests largely on consensus practice and observational data. The mainstay is high-dose intravenous corticosteroids, typically methylprednisolone administered for three to five days, frequently followed by an oral prednisolone taper over several weeks; an adequate taper is widely considered to reduce the risk of early relapse. For patients with insufficient response or severe presentations, intravenous immunoglobulin (IVIG) and plasma exchange represent established second-line options, with plasma exchange generally reserved for fulminant or steroid-refractory disease. Immunosuppressive or chemotherapeutic agents have been used anecdotally in the most severe cases. Supportive care—including management of seizures, raised intracranial pressure, aspiration risk, and rehabilitation services—forms an integral part of treatment.

Prognosis

ADEM is generally regarded as having a favorable prognosis. The illness is usually monophasic, and improvement typically begins within days of treatment initiation. Complete or near-complete recovery occurs in roughly half to three-quarters of patients within weeks to months, although residual deficits—most commonly motor impairment, visual disturbance, cognitive or behavioral change, or fatigue—persist in a minority. Reported mortality in contemporary series is low, on the order of a few percent. Relapse risk is estimated at approximately ten to twenty percent in children; occurrence of a second, non-encephalopathic demyelinating event, evolution of new lesions on serial MRI, or the appearance of oligoclonal bands should prompt reassessment for MS or MOGAD. Long-term neurocognitive outcome studies indicate that some children exhibit subtle deficits in attention, memory, or executive function despite full motor recovery, underscoring the value of longitudinal follow-up.

Variants and Related Disorders

• Acute hemorrhagic leukoencephalitis (AHL, Hurst disease) is a rare, fulminant hyperacute variant characterized pathologically by necrotizing, hemorrhagic, fibrinoid necrosis of venules with intense inflammation. It typically follows a explosive course with high fever, rapidly progressive coma, and substantial mortality, though survival with aggressive immunotherapy has been documented.
• Multiphasic disseminated encephalomyelitis (MDEM) denotes recurrence of encephalopathy and new multifocal MRI lesions consistent with the diagnostic criteria, separated by at least three months; it is uncommon and, in contemporary cohorts, strongly associated with persisting MOG-IgG.
• ADEM with MOG antibodies is now widely classified within MOG antibody–associated disease (MOGAD). Such patients may experience relapses, particularly optic neuritis or myelitis, and require tailored long-term monitoring of antibody status and clinical course.

Impact and Significance

ADEM occupies a distinctive place in neurology and immunology. Historically, it provided the first clinical framework linking systemic infections and vaccinations to CNS autoimmunity, and its pathological identity with experimental autoimmune encephalomyelitis laid the groundwork for the modern understanding of demyelinating disease. Clinically, the entity remains pivotal in pediatric neurology: distinguishing ADEM from the first attack of MS has major consequences for counseling, surveillance, and the use of disease-modifying therapy, while recognition of MOG-IgG has reshaped classification and follow-up strategies. Public-health significance stems from its historical association with vaccines; although modern vaccination is causally linked to only a vanishingly small fraction of cases, precise epidemiological surveillance of ADEM continues to inform vaccine safety assessment. Scientifically, ADEM serves as a natural model for studying molecular mimicry, blood–brain barrier physiology, and the mechanisms by which transient immune dysregulation may either resolve completely or seed chronic demyelinating disease, and ongoing research into its immunopathogenesis continues to illuminate the broader spectrum of inflammatory disorders of the central nervous system.